Market revenue in 2023 | USD 272.2 million |
Market revenue in 2030 | USD 663.9 million |
Growth rate | 13.6% (CAGR from 2023 to 2030) |
Largest segment | Kits & reagents |
Fastest growing segment | Services |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Instruments, Kits & Reagents, Services |
Key market players worldwide | Thermo Fisher Scientific Inc, Lonza Group Ltd, Merck KGaA, Charles River Laboratories International Inc, Asahi Kasei Corp, Sartorius AG, Eurofins Scientific SE, PromoCell GmbH, ATCC, InvivoGen |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mycoplasma testing market will help companies and investors design strategic landscapes.
Kits & reagents was the largest segment with a revenue share of 57.68% in 2023. Horizon Databook has segmented the Europe mycoplasma testing market based on instruments, kits & reagents, services covering the revenue growth of each sub-segment from 2018 to 2030.
The demand for mycoplasma testing in Europe is growing due to multiple factors integral to the region's robust biopharmaceutical and biotechnology sectors. One primary driver is the European Medicines Agency's (EMA) stringent regulatory standards for ensuring the safety and efficacy of biological products, which mandate rigorous mycoplasma testing.
These regulations necessitate comprehensive screening to detect and eliminate mycoplasma contamination, thereby safeguarding research integrity and public health. The increasing investment in biotechnology and life sciences research across Europe has further spurred the need for advanced mycoplasma testing.
The EU’s Horizon Europe program, which funds innovative scientific research, emphasizes the importance of high-quality standards in biomedical research, driving the adoption of advanced mycoplasma detection technologies, such as qPCR and Next-Generation Sequencing (NGS).
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe mycoplasma testing market , including forecasts for subscribers. This continent databook contains high-level insights into Europe mycoplasma testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account